Objective To investigate the influence of glycemic variability on the HbA1c level in elderly male patients with type 2 diabetes (T2DM). Methods The 24-h glucose profiles were obtained using a continuous glucose monitoring system in 291 elderly male type 2 diabetic patients. The relationship between the glycemic variability and HbA1c level was assessed in these patients. Results The mean amplitude of glycemic excursions (MAGE) in patients with HbA1c " 7.0% was significantly higher than in patients with HbA1c <7.0% (4.33±1.67 vs. 3.48±1.46 mmol/L, p<0.001). A simple (Pearson's) correlation analysis indicated that the MAGE was significantly correlated with the HbA1c (r= 0.229, p<0.001). Compared with the lowest quartile, the highest quartile of the MAGE was associated with a significantly increased risk of having a HbA1c " 7.0% after multiple adjustments (p for trend <0.001). Conclusion The glycemic variability had a significant influence on the HbA1c level in elderly male patients with T2DM. The present data suggests that patients with higher glycemic variability might have higher HbA1c levels.
Introduction
An increased incidence of diabetes is observed in the elderly. A previous national study has documented that 20.4% of patients over the age of 60 years had diabetes in the Chinese population (1) . It is important to note that aging is associated with decreased β cell function (2) , and postprandial β cell dysfunction was demonstrated to strongly correlate with glycemic variability in type 2 diabetic patients using oral hypoglycemic agents (3) . The glycemic variability has been regarded as an independent risk factor that contributes to the development of chronic diabetic complications (4, 5) , and some scholars have argued that it should be included as another therapeutic target in diabetes management (6) . Debate remains as to whether the glycemic variability is associated with sustained chronic hyperglycemia as measured by the HbA1c. In the study by Engler et al. (7) , patients with a HbA1c >7% had a higher glycemic variability, leading to increased oxidative stress in patients with type 2 diabetes, compared with patients with a HbA1c ! 7%. To further investigate the influence of glycemic variability on the HbA1c level in patients with type 2 diabetes, a cross-sectional study was conducted among elderly male patients who had received continuous glucose monitoring.
Materials and Methods

Study design
The present study was conducted as a cross-sectional study, which enrolled 291 elderly male inpatients with type 2 diabetes who received continuous glucose monitoring (CGM). The inclusion criteria comprised a diagnosis of type 2 diabetes, male gender, age " 60 years, and subjects who treated with diet, oral hypoglycemic agents or insulin. The exclusion criteria were changes in lifestyle, diet or treatment, and acute illness within 1 month before receiving Data are the means ± SD or numbers (%).
CGM, or concomitant medications that may affect glucose metabolism, such as glucocorticoids and thyroid hormones.
The data collection and analysis of the study subjects were approved by the local ethics committee. A standardized questionnaire was adopted by trained data collectors to obtain information on demographic characteristics, as well as the personal and family medical history. The participants underwent a routine examination including height, body weight, waist circumference, systolic blood pressure, and diastolic blood pressure. The HbA1c, fasting plasma glucose, postprandial plasma glucose, total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were measured before initializing CGM. The plasma glucose level was measured with a glucose oxidase method. The HbA1c was measured using a routine HPLC method with a Variant II HbA1c analyzer (Bio-Rad Laboratories, Hercules, CA, USA). The inter-assay coefficient of variability of HbA1c was 0.49-0.94%, and the intra-assay coefficient of variability was 1.63-2.29%.
Continuous glucose monitoring (CGM)
The glycemic variability was determined by the 24-hour Medtronic MiniMed Continuous Glucose Monitoring System TM (CGMS; Medtronic MiniMed, Northridge, CA, USA). The CGM system sensor (Medtronic, Northridge, CA) was inserted into all subjects by the same specialized technician and calibrated according to the standard operating guidelines for 72 hours before being removed. A disciplinary timing of the diet was required in the hospital, including 07:15 A.M. for breakfast, 11:15 A.M. for lunch, and 5:15 P.M. for dinner. The MiniMed Solutions Sensor TM 3.0 software package was used to download data. The manufacturer's accuracy criteria were applied: a correlation between the sensor and meter readings of at least 0.79 and a mean absolute difference of at most 28% (8) . Data not meeting these criteria were excluded. The glycemic variability quantified as the mean amplitude of glycemic excursions (MAGE) was calculated for all study subjects.
Statistical analysis
The data are presented as the means ± standard deviation (SD). A 48 hours recording from 0:00 on day 2 to 0:00 on day 4 of the CGM were calculated to quantify the MAGE. Comparisons of quantitative variables among groups were performed using an independent-samples t-test or a one-way analysis of variance (ANOVA). Comparisons of the thera- peutic strategies between two groups were determined by the χ 2 test. A univariate analysis was performed to assess the association between the glycemic variability and selected variables. The independent significant risk factors for an abnormal HbA1c (HbA1c ! 7.0%) were evaluated by a multivariate logistic regression analysis in order to calculate the standardized odds ratios after adjustment by several relevant risk factors. p values <0.05 were considered to be statistically significant.
Results
A total of 311 elderly male inpatients with type 2 diabetes who received CGM were identified. Among these patients, 20 subjects were excluded because they did not meet the accuracy criteria. Ultimately, the data of the remaining 291 (93.6%) patients were included in the final analysis. These patients had a mean age of 76.3±9.1 years, diabetes duration of 16.4±9.7 years, BMI of 25.2±2.6 kg/m 2 , and HbA1c of 7.10±1.22%.
The clinical characteristics of study subjects are shown in Table 1 . When categorized by HbA1c, the MAGE in patients with a HbA1c ! 7.0% was significantly higher than that in patients with a HbA1c <7.0% (4.33±1.67 vs. 3.48± 1.46 mmol/L, p<0.001), while the age and BMI were comparable in the two groups. The differences in therapeutic strategies in the two groups were compared. The percentage of patients who used metformin (56.5% vs. 33.3%) or insulin (71.0% vs. 43.8%) in patients with a HbA1c ! 7.0% was significantly higher than that in patients with a HbA1c <7.0% (p<0.01), and no difference was detected regarding diet, or the use of sulfonylureas, glinides, thiazolidinediones, or α-Glucosidase inhibitors.
When the subjects were divided into quartiles based on the MAGE level, the HbA1c level gradually increased across the MAGE quartiles (Table 2, p<0.001). The correlations between the glycemic variability and selected variables were analyzed (Table 3) . A simple (Pearson's) correlation analysis indicated that the MAGE was significantly correlated with the HbA1c, and the correlation coefficient was r = 0.229 (p<0.001).
To further investigate whether the glycemic variability was correlated with the HbA1c, logistic regression models with clinical factors associated with the risk of an abnormal HbA1c (HbA1c ! 7.0%) were evaluated. Compared with the lowest quartile of the MAGE, the highest quartile had a 6.45-fold higher risk of having an abnormal HbA1c (p for trend <0.001, Table 2 ) after adjustment for age, BMI, waist circumference, and diabetic duration in model 1. When further adjusted for fasting plasma glucose, postprandial plasma glucose, and mean blood glucose based on model 1, a 5.28-fold increased risk of having an abnormal HbA1c was detected in the highest quartile in model 2 (p for trend <0.001). According to model 3, the OR (95%CI) of the highest quartile was 4.76 (1.74-13.1) after further adjusting for insulin, sulfonylurea or glinides therapy, when compared with the lowest quartile of the MAGE.
Discussion
In the present study, the glycemic variability measured by CGM was significantly higher in patients with a HbA1c ! 7.0% even though the age and BMI were comparable between groups. A multivariate logistic regression analysis showed that the MAGE was significantly associated with an abnormal HbA1c, even after adjusting for the plasma glucose level, treatment, and other clinical factors, which implied that the glycemic variability had a significant influence on the HbA1c level, and elderly male patients with type 2 diabetes with a higher MAGE are likely to have a higher HbA1c.
Our observations were inconsistent with several previous studies. Sartore et al. (9) systematically investigated the relationship between the HbA1c levels and glucose variability indicators using CGM, and found that the HbA1c was not significantly correlated with glucose variability in patients with type 1 and type 2 diabetes. Schmitz et al. (10) demonstrated that the HbA1c could represent an integrated measurement of sustained hyperglycemia during the previous few months, but could not reflect acute glucose fluctuations and postprandial glycemic variability. In the study by Kohnert et al. (11) , 63 primary care patients with type 2 diabetes received CGM to evaluate the association between the HbA1c and glycemic variability, and they indicated that the HbA1c was related to chronic hyperglycemia, but not glucose variability, in patients with well-controlled type 2 diabetes. Derr et al. (12) also suggested that the HbA1c reflected the mean blood glucose and was not meaningfully affected by the glycemic variability as measured by self monitoring of blood glucose (SMBG). However, our data support the hypothesis that the glycemic variability has a significant influence on the HbA1c level. The relatively larger number of subjects analyzed and use of CGM as an optimal measure to evaluate the glycemic variability in this study might have contributed to our observations. Our findings could have potentially important implications for diabetes management. As one of the different components of dysglycemia in diabetes, acute glucose fluctuations are associated with chronic sustained hyperglycemia, which is expressed as more intensive glucose fluctuation, leading to poorer glucose control. From the onset of type 2 diabetes, β cell deficiency plays a significant role in explaining dysglycemia (13, 14) , even though there are other factors such as life style, therapeutic strategies, individual differences, and so on that affect the condition. Since there is insufficient insulin secretion for accurate regulation in patients with type 2 diabetes (15), glucose-related metabolic disorders might expose subjects to increased glycemic variability, in addition to chronic sustained hyperglycemia. In addition, aging might have a significant influence on pancreatic β cell function. Our previous study suggested that β-islet cell function decreased gradually with age (16) , and a significant reduction in proliferation and an increase in the frequency of apoptotic β cells were detected in the islets of elderly rats. In a study by Tschen et al. (17) , the β cell proliferation and the capacity of β cells to regenerate were confirmed to decline with age. Therefore, not only chronic sustained hyperglycemia, but also increased glycemic variability, are associated with pancreatic β cell deficiency (3), especially in elderly subjects.
Despite the various publications supporting our present finding that the glycemic variability affects the HbA1c, there are several limitations to the present study that should be kept in mind. First, the cross-sectional study design is lim-ited in its ability to eliminate causal relationships between the HbA1c and glycemic variability. The influence of glycemic variability on the HbA1c level should be verified in future prospective follow-up studies. Second, a larger sample size and more geographic representation are required to further clarify the association of the glycemic variability with the HbA1c. Third, we had limited information about the patients' lifestyles. However, we have relatively complete data on the clinical variables, including the results of physical examinations, lab tests, and treatment strategies. Finally, information about the doses of antihyperglycemic agents and the treatment duration, which may help to analyze the factors influencing the HbA1c, was not available.
In conclusion, we found that the glycemic variability was associated with the HbA1c in elderly male patients with type 2 diabetes. The glycemic variability had a significant independent influence on the HbA1c level, which was inconsistent with several, but not all previous studies. Further studies are therefore warranted to confirm the results.
